A personal care or pharmaceutical composition

Abstract

Disclosed is a pharmaceutical or personal care composition comprising acetyl amino acid compound and vitamin C compound, wherein the molar ratio of the acetyl amino acid compound to the vitamin C compound is at least 7:1.

Description

[0001] P0001265W01 CPL

[0002] 1

[0003] A PERSONAL CARE OR PHARMACEUTICAL COMPOSITION

[0004] Field of the Invention

[0005] The present invention relates to a pharmaceutical or personal care composition comprising 5 acetyl amino acid compound and vitamin C compound, wherein the molar ratio of the acetyl amino acid compound to the vitamin C compound is at least 7:1. It was unexpectedly found that such composition is capable of significantly upregulating the expression of COL17A1 (Collagen Type XVII Alpha 1 Chain) gene.

[0006] Background of the Invention

[0007] The skin is a primary barrier of the human body. It protects the organs in the body from external stimulations. It is subject to intrinsic aging and extrinsic aging. Skin aging is a complex process, and alterations in human skin due to aging have distinct characteristics as compared to other organs. Characteristics of intrinsic or chronological skin aging include dryness, visible free lines 15 and wrinkles, uneven skin pigmentation, loss of elasticity and skin sagging. Extrinsic factors including exposure to sunlight, pollutants and cigarette smoke can accelerate the skin aging process, especially on the face.

[0008] As humans age, their skin becomes thinner, more fragile, drier, shows abnormal pigmentation, 20 and heals wounds more slowly. The fragility of human skin during aging is partly due to the remodeling of the dermal-epidermal junction, particularly the hemidesmosomes component. Collagen XVII (COL17), a transmembrane protein in hemidesmosomes, regulates skin homeostasis, aging, and wound repair by mediating stem cell interactions with surrounding cells and the matrix. Therefore, Promoting the production of collagen XVII through upregulating the expression of COL17A1 (Collagen Type XVII Alpha 1 Chain) gene is an efficient way of providing anti-aging, and / or wound repair benefit.

[0009] Therefore, the present inventors have recognized that there is a need to develop solution to enhance the expression of COL17A1 gene. It was surprisingly found that by combining acetyl 30 amino acid compound and vitamin C compound, with a molar ratio of the acetyl amino acid compound to the vitamin C compound being at least 7:1, the expression of COL17A1 gene was significantly upregulated.P0001265W01 CPL

[0010] 2

[0011] Summary of the Invention

[0012] In a first aspect, the present invention is directed to a pharmaceutical or personal care composition comprising acetyl amino acid compound and vitamin C compound, wherein the molar ratio of the acetyl amino acid compound to the vitamin C compound is at least 7:1.

[0013] 5

[0014] In a second aspect, the present invention is directed to a method of providing the skin benefits selected from the group consisting of enhancing collagen production in the skin, improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging, would healing, and enhancing the expression of COL17A1 gene, comprising a step of topically applying to the skin the composition of the composition of the present invention.

[0015] In a third aspect, the present invention is directed to use of the composition of the present invention for providing the skin benefits selected from the group consisting of enhancing collagen production in the skin, improving skin elasticity, reducing the appearance of wrinkles, 15 reducing sagging, anti-aging, would healing, and enhancing the expression of COL17A1 gene.

[0016] All other aspects of the present invention will more readily become apparent upon considering the detailed description and examples which follow.

[0017] 20 Detailed Description of the Invention

[0018] Except in the examples, or where otherwise explicitly indicated, all numbers in this description indicating amounts of material or conditions of reaction, physical properties of materials and / or use may optionally be understood as modified by the word “about”.

[0019] All amounts are by weight of the composition, unless otherwise specified.

[0020] It should be noted that in specifying any range of values, any particular upper value can be associated with any particular lower value.

[0021] 30 For the avoidance of doubt, the word “comprising” is intended to mean “including” but not necessarily “consisting of” or “composed of’. In other words, the listed steps or options need not be exhaustive.P0001265W01 CPL

[0022] 3

[0023] The disclosure of the invention as found herein is to be considered to cover all embodiments as found in the claims as being multiply dependent upon each other irrespective of the fact that claims may be found without multiple dependency or redundancy.

[0024] 5 Where a feature is disclosed with respect to a particular aspect of the invention (for example a composition of the invention), such disclosure is also to be considered to apply to any other aspect of the invention (for example a method of the invention) mutatis mutandis.

[0025] The composition of the present invention comprises acetyl amino acid compound. The acetyl amino acid compound as used herein typically refers to the hydrogen C or N of the amino acid is substituted by acetyl group, including its free acid, amide, ester, lactone, isomer, salt thereof, and / or a combination thereof. The acetyl amino acid compound preferably refers to compound selected from the group consisting of acetyl glutamic acid (e.g., N-acetyl glutamic acid); acetyl glutamine (e.g., N-acetyl glutamine); acetyl methionine (e.g., N-acetyl methionine); acetyl 15 tyrosine (e.g., N-acetyl tyrosine); free acid, amide, ester, lactone, isomer, thereof; salt thereof, and combination thereof. More preferably, the acetyl amino acid compound comprises acetyl methionine compound, preferably the acetyl amino acid compound is acetyl methionine compound.

[0026] 20 “Salts” as used in the present invention, includes but is not limited to ammonium, calcium, magnesium, manganese, potassium, sodium, tetraalkylammonium, trialkylammonium, or a combination thereof.

[0027] In a further aspect, the acetyl amino acid compound or acetyl methionine compound may be 25 present in any of its isomeric forms and in combinations thereof. “Isomers”, as used herein, is meant to include D-isomers, L-isomers, and / or DL-isomers for a particular compound. Thus, the acetyl amino acid compound comprises its D-isomer form, L-isomer form, DL-isomer form, or a combination thereof. For example, N-acetyl methionine may be present in any of its isomeric forms and in combinations thereof. For example, N-acetyl-DL-methionine (i.e. , is in its DL- isomer form), N-acetyl-D-methionine (i.e., is in its D-isomer form) and N-acetyl-L-methionine (i.e., is in its L-isomer form).

[0028] Typically, the acetyl amino acid compound is present in the composition disclosed herein in an amount of from 0.0001 to 10%, or from 0.0005 to 8%, or from 0.001 to 6%, or from 0.005 to 5%, 35 or from 0.01 to 4%, or from 0.02 to 3.5%, or from 0.025 to 3%, or from 0.05 to 2.5%, or fromP0001265W01 CPL

[0029] 4

[0030] 0.1 to 2.5%, or from 0.1 to 2%, or from 0.2 to 1.5% by weight of the composition. In another aspect, the acetyl amino acid compound is present in the composition in an amount from 0.001 to 5%, or from 0.005 to 4%, or from 0.01 to 3%, or from 0.05 to 3%, or from 0.1 to 3%, or from 0.25 to 2% by weight of the composition.

[0031] 5

[0032] Where the composition comprises acetyl methionine, acetyl methionine (or N-acetyl methionine) has the following structural formula (which is available from numerous suppliers, including Sigma-Aldrich):

[0033]

[0034] In one aspect, at least 50%, or at least 70%, or at least 80%, or at least 90%, or 100% by weight of the acetyl amino acid compound is acetyl methionine. In one aspect, from 50 to 100%, or from 60 to 100%, or from 70 to 100%, or from 80 to 100%, or from 90 to 100%, or from 80 to 95%, or from 85 to 95%, by weight, of the acetyl amino acid compound is acetyl methionine. 15

[0035] The acetyl methionine compound refers to compound selected from acetyl methionine, salt of acetyl methionine, ester of acetyl methionine, amide of acetyl methionine, salt of ester of acetyl methionine, or salt of amide of acetyl methionine, or a mixture thereof. Preferably, the acetyl methionine compound is selected from acetyl methionine, salt of acetyl methionine, ester of 20 acetyl methionine, salt of ester of acetyl methionine, or a mixture thereof. More preferably, the acetyl methionine compound is selected from acetyl methionine, salt of acetyl methionine, or a mixture thereof. The particularly preferred acetyl methionine compound is acetyl methionine. Preferably, the acetyl methionine compound is Acetyl-DL-methionine, N-Acetyl-L-methionine, Acetyl-D-methionine, or a combination thereof.

[0036] Typically, the acetyl methionine compound is present in the composition disclosed herein in an amount of from 0.0001 to 10%, or from 0.0005 to 8%, or from 0.001 to 6%, or from 0.005 to 5%, or from 0.01 to 4%, or from 0.02 to 3.5%, or from 0.025 to 3%, or from 0.05 to 2.5%, or from 0.1 to 2.5%, or from 0.1 to 2%, or from 0.2 to 1.5% by weight of the composition. In another 30 aspect, the acetyl methionine compound is present in the composition in an amount from 0.001 to 5%, or from 0.005 to 4%, or from 0.01 to 3%, or from 0.05 to 3%, or from 0.1 to 3%, or from 0.25 to 2% by weight of the composition.P0001265W01 CPL

[0037] 5

[0038] The vitamin C compound refers to compound selected from ascorbic acid (also known as vitamin C), isoascorbic acid, ester or ether thereof, or salt of ascorbic acid, salt of ester of ascorbic acid, or salt of ether of ascorbic acid. Any physiologically acceptable salt of ascorbic acid may be used. Salts of ascorbic acid comprise alkali metal, alkaline earth metal salts, 5 ammonium salt, those derived from monoethanolamine, diethanolamine, amino acids salt such as arginine or lysine, or combination thereof. Suitable ascorbic acid esters are those in which one or more hydroxy groups in the 2-, 3-, 5- and / or 6-positions are fatty acid ester, sulphate or phosphate. Preferably, the Vitamin C compound is ester of ascorbic acid and / or salt thereof. More preferably the vitamin C compound is ascorbyl phosphate. Still even more preferably, vitamin C compound is magnesium ascorbyl phosphate and / or sodium ascorbyl phosphate.

[0039] Preferably, the vitamin C compound comprises ascorbic acid, calcium ascorbate dihydrate, sodium ascorbate, ascorbyl glycoside, glyceryl ascorbate, 3-O-ethyl-L-ascorbic acid, methoxy peg-7 ascorbic acid, ascorbyl stearate, ascorbyl tetraisopalmitate, tetrahexyldecyl ascorbate, 15 ascorbyl phosphate, ascorbyl palmitate, or a mixture thereof. More preferably, the vitamin C compound comprises ascorbic acid, ascorbyl phosphate, sodium ascorbate, ascorbyl glucoside, ascorbyl tetraisopalmitate, ascorbyl palmitate, or a mixture thereof. Even more preferably, the vitamin C compound comprises ascorbic acid, ascorbyl phosphate, ascorbyl glucoside, glyceryl ascorbate, ascorbyl tetraisopalmitate, ascorbyl palmitate, or a mixture thereof. Even more 20 preferably, the vitamin C compound comprises ascorbyl phosphate, ascorbyl glucoside, ascorbyl tetraisopalmitate, ascorbyl palmitate, or a mixture thereof. Still even more preferably, the vitamin C compound comprises ascorbyl phosphate. Most preferably, the vitamin C compound is ascorbyl phosphate.

[0040] 25 Preferably, the amount of the vitamin C compound of the is 0.0001 to 8% by weight of the composition, more preferably 0.005 to 5% by weight, even more preferably 0.02 to 2% and most preferably 0.1 to 1.2% by weight of the composition. Preferably, the amount of ester of ascorbic acid is 0.0001 to 8% by weight of the composition, more preferably 0.005 to 5% by weight, even more preferably 0.02 to 2% and most preferably 0.1 to 1.2% by weight of the 30 composition. Preferably, the amount of ascorbyl phosphate is 0.0001 to 8% by weight of the composition, more preferably 0.005 to 5% by weight, even more preferably 0.02 to 2% and most preferably 0.1 to 1.2% by weight of the composition.P0001265W01 CPL

[0041] 6

[0042] Preferably, the molar ratio of the acetyl amino acid compound to the vitamin C compound is 7:1 to 300:1, more preferably 7:1 to 80:1, even more preferably 7:1 to 30:1, and still even more preferably 8:1 to 15:1.

[0043] 5 Preferably, the present invention provides a personal care composition comprising acetyl methionine compound and vitamin C compound, wherein the molar ratio of acetyl methionine compound to the vitamin C compound is at least 7:1.

[0044] Preferably, the molar ratio of the acetyl methionine compound to the vitamin C compound is 7:1 to 300:1, more preferably 7:1 to 80:1, even more preferably 7:1 to 30:1, and still even more preferably 8:1 to 15:1.

[0045] Preferably, the present invention provides a personal care composition comprising acetyl methionine compound and vitamin C compound, wherein the acetyl methionine compound is 15 selected from acetyl methionine, salt of acetyl methionine, or a mixture thereof, and the molar ratio of the total acetyl methionine and salt of acetyl methionine to the vitamin C compound is at least 7:1.

[0046] Preferably, the total salt of acetyl methionine and salt of acetyl methionine is present in amount 20 of 0.000001 to 10%, more preferably 0.00001 to 5%, even more preferably 0.0001 to 3% and still even more preferably 0.001 to 1% by weight of the composition.

[0047] Preferably, the molar ratio of the total acetyl methionine and salt of acetyl methionine to the vitamin C compound is 7:1 to 300:1, more preferably 7:1 to 80:1, even more preferably 7:1 to 25 30:1, and still even more preferably 8:1 to 15:1.

[0048] Preferably, the present invention provides a personal care composition comprising acetyl methionine compound and vitamin C compound, wherein the acetyl methionine compound is selected from acetyl methionine, salt of acetyl methionine, or a mixture thereof, the vitamin C compound is ester of ascorbic acid, and the molar ratio of the total acetyl methionine and salt of acetyl methionine to the ester of ascorbic acid is at least 7:1.

[0049] Preferably, the molar ratio of the total acetyl methionine and salt of acetyl methionine to the ester of ascorbic acid is 7:1 to 300:1, more preferably 7:1 to 80:1, even more preferably 7:1 to 35 30:1, and still even more preferably 8:1 to 15:1.P0001265W01 CPL

[0050] 7

[0051] Preferably, the present invention provides a personal care composition comprising acetyl methionine and ascorbyl phosphate, wherein molar ratio of the acetyl methionine to the ester of ascorbyl phosphate is at least 7:1.

[0052] 5 Preferably, the acetyl methionine is present in amount of 0.000001 to 10%, more preferably 0.00001 to 5%, even more preferably 0.0001 to 3% and still even more preferably 0.001 to 1% by weight of the composition.

[0053] Preferably, the molar ratio of the acetyl methionine to the ascorbyl phosphate is 7:1 to 300:1, more preferably 7:1 to 80:1, even more preferably 7:1 to 30:1, and still even more preferably 8:1 to 15:1.

[0054] The composition may comprise substituted resorcinol. Substituted resorcinol typically refers to that at least one hydrogen on the ring structure and / or on a hydroxy group of the resorcinol 15 replaced with an alkyl group, phenyl alkyl group, or heterocyclic group. Preferably, the substituted resorcinol is 4-substituted resorcinol. Preferably, the substituted resorcinol is selected from 4-ethyl resorcinol, 4-butyl resorcinol, 4-hexyl resorcinol, phenylethyl resorcinol, thiamidol, or a mixture thereof, more preferably, the substituted resorcinol is selected from 4- ethyl resorcinol, 4-butyl resorcinol, 4-hexyl resorcinol, or a mixture thereof and even more 20 preferably, the substituted resorcinol comprises 4-hexyl resorcinol. The amount of the substituted resorcinol is preferably in the range of 0.00001 to 10%, more preferably from 0.001 to 5% and most preferably from 0.1 to 0.6% by weight of the total amount of the composition.

[0055] Preferably, the composition comprises Vitamin B3 compounds (including derivatives of vitamin 25 B3). The vitamin B3 compounds comprises niacin, nicotinic acid, niacinamide or a mixture thereof. The most preferred vitamin B3 compound is niacinamide. Amount of Vitamin B3 compounds may be 0.1 to 10%, preferably 0.5 to 5% by weight of the composition. 2- mercaptonicotinoyl glycine may also be included in the composition. Amount of 2- mercaptonicotinoyl glycine may be 0.0001 to 10%, preferably 0.01 to 1% by weight of the composition.

[0056] Preferably, the composition comprises a glutamate source selected from the group consisting of glutamine, glutamine ester, glutamic acid, pyroglutamic acid, salts, and mixtures thereof. More preferably, the composition comprises pyroglutamic acid and / or salt of pyroglutamic acid. Even 35 more preferably, the composition comprises sodium salt of pyroglutamic acid. Preferably, theP0001265W01 CPL

[0057] 8

[0058] glutamate source is present in amount of 0.0001 to 10% by weight of the composition, more preferably 0.001 to 6%, even more preferably 0.01 to 3% by weight of the composition.

[0059] The composition may optionally comprise whitening pigment. Whitening pigments are typically 5 particles of high refractive index materials. For example, the whitening pigment may have a refractive index of greater than 1.3, more preferably greater than 1.8 and most preferably from 2.0 to 2.7. Examples of such whitening pigment are those comprising bismuth oxy-chloride, boron nitride, barium sulfate, mica, silica, titanium dioxide, zirconium oxide, aluminium oxide, zinc oxide or combinations thereof. More preferred whitening pigment are particles comprising 10 titanium dioxide, zinc oxide, zirconium oxide, mica, iron oxide or a combination thereof. Even more preferred whitening pigment are particles comprising zinc oxide, zirconium oxide, titanium dioxide or a combination thereof as these materials have especially high refractive index. Still even more preferably the whitening pigment is selected from titanium dioxide, zinc oxide or a mixture thereof and most preferred whitening pigment is titanium dioxide. The average diameter 15 of whitening pigment is typical from 15 nm to 1 micron, more preferably from 35 nm to 800 nm, even more preferably from 50 nm to 500 nm and still even more preferably from 100 to 300 nm. Amount of whitening pigment may be 0.1 to 15%, preferably 0.5 to 5% by weight of the composition.

[0060] 20 Preferably, the composition comprises polyhydric alcohol. Polyhydric alcohols may be selected from group of glycerin, propylyene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol or a mixture thereof. Most preferred polyhydric alcohol is glycerol known also as glycerin. The amount of polyhydric alcohol may range

[0061] 25 anywhere from 0.1 to 20%, preferably 0.5 to 15% and more preferably 2 and 10% by weight of the composition.

[0062] Preferably, the composition comprises emollient materials. Suitable emollient materials include silicones, hydrocarbons, triglycerides or a mixture thereof. These silicones may be organic, 30 silicone-containing or fluorine-containing, volatile or non-volatile, polar or non-polar.

[0063] Hydrocarbons may include mineral oil, petrolatum and polyalpha-olefins. Examples of preferred volatile hydrocarbons include polydecanes such as isododecane and isodecane (e.g.

[0064] Permethyl-99A which is available from Presperse Inc.) and the C7-C8 through C12-C15 isoparaffins (such as the Isopar Series available from Exxon Chemicals). Illustrative

[0065] 35 triglycerides but not limiting are sunflower seed oil, cotton oil, canola oil, soybean oil, castor oil,P0001265W01 CPL

[0066] 9

[0067] borage oil, olive oil, shea butter, jojoba oil and mixtures thereof. Mono- and di- glycerides may also be useful. Particularly preferable are glyceryl monostearate and glyceryl distearate.

[0068] Preferably, the composition comprises moisturizing agents. Particularly preferred moisturizing 5 agents includes, petrolatum, aquaporin manipulating actives, oat kernel flour, substituted urea like hydroxyethyl urea, hyaluronic acid and / or its precursor N-acetyl glucosamine, hyaluronic acid and / or its precursor N-acetyl glucosamine, or a mixture thereof.

[0069] Some compositions may include thickeners. These may be selected from cellulosics, natural gums and acrylic polymers but not limited by this thickening agent types. Among the cellulosics are sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations thereof. Suitable gums include xanthan, pectin, karaya, agar, alginate gums and combinations thereof. Among the acrylic thickeners are homopolymers and copolymers of acrylic and methacrylic acids including carbomers such as Carbopol 1382, Carbopol 982, 15 llltrez, Aqua SF-1 and Aqua SF-2 available from the Lubrizol Corporation. Amounts of thickener may range from 0.01 to 3% by weight of the active polymer (outside of solvent or water) in the compositions.

[0070] In addition, the compositions of the invention may further include 0.5 to 10% by weight of 20 sequestering agents, such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene / Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.

[0071] 25 The composition may comprise water in amount of 10 to 96% by weight of the composition, more preferably from 25 to 92%, even more preferably from 42 to 88%, most preferably from 55 to 82% by weight of the composition.

[0072] Preferably, the composition has a viscosity of at least 10 mPa s, more preferably in the range 30 to 10000 mPa s, even more preferably 50 to 5000 mPa s, and most preferably 100 to 2000 mPa s, when measured at 20 degrees C at a relatively high shear rate of about 20 s'1.

[0073] Preferably, the composition is an emulsion, more preferably an oil-in-water emulsion. Preferably the composition is a fluid at 25 °C and atmospheric pressure.

[0074] 35P0001265W01 CPL

[0075] 10

[0076] Preferably, the composition is an emulsion, more preferably an oil-in-water emulsion.

[0077] Preferably, the personal care composition is a skin care composition. The skin care composition refers to a composition suitable for topical application to human skin, including leave-on and wash-off products but preferably leave-on compositions. The term “leave-on” as used with 5 reference to compositions herein means a composition that is applied to or rubbed on the skin and left thereon. The term “wash-off” as used with reference to compositions herein means a skin cleanser that is applied to or rubbed on the skin and rinsed off substantially immediately subsequent to application. Preferably the composition is a fluid liquid, and particularly a moisturizer rather than a make-up product. The term "skin" as used herein includes the skin on the face, neck, chest, abdomen, back, arms, under arms, hands, and legs. Preferably “skin” means includes the skin on the face and under arms, more preferably skin means skin on the face other than lips and eyelids.

[0078] Preferably, the composition is a topical composition. Preferably, the composition may be in the 15 form of cream, lotion, ointment, solution, suspension, emulsion, paste, gel, powder, powder foundation, emulsion foundation, wax foundation, or spray. More preferably, the composition may be formulated in the form of cream, lotion, ointment, emulsion, gel, or a spray.

[0079] Preferably the use is non-therapeutic. Preferably the method is non-therapeutic. The term non- 20 therapeutic typically means for cosmetic purposes and not curative or therapeutic purposes.

[0080] The following examples are provided to facilitate an understanding of the invention. The examples are not intended to limit the scope of the claims.

[0081] Examples

[0082] Materials

[0083]

[0084] Example 1

[0085] This Example demonstrates the synergistic upregulation of gene expression by combining 30 Acetyl methionine and Vitamin C compound.P0001265W01 CPL

[0086] 11

[0087] The normal human epidermal keratinocytes (NHEKs) (Biocell, Xi’an, China, LOT: Ep24070801) were cultured in keratinocyte culture medium (KcGrowth, Biocell, Xi’an, China) and plated in 6- well plates. When the cell confluency reached 40% to 60%, the culture medium was replaced with medium together with or without actives for 24 hours, the total RNA for NHEKs was 5 extracted using RNAex Pro reagent (Accurate Biotechnology, Cat: AG21102) according to manufacturer’s protocol.

[0088] The extracted RNA was quantified using Nanodrop spectrometer (Thermo Fisher Scientific, Waltham, MA, US) and reverse transcribed to generate the template cDNA using the Evo M- 10 MLV RT Premix for qPCR (Accurate Biotechnology, Cat: AG11706) according to manufacturer’s protocol. Gene expression of COL17A1 gene was analyzed by polymerase chain reaction (PCR) using SYBR® Green Premix Pro Taq HS qPCR Kit (Accurate Biotechnology, AG11701). The actin beta (ACTS) gene was selected as the housekeeping gene and all data on relative expression of the target genes was normalized to ACTB gene. The fold changes in expression were calculated relative to the blank control (medium having no active). All tests were conducted at least three times and Table 1 shows the fold change of the gene expression for COL17A1.

[0089] Table 1

[0090]

[0091] 20 *The level of the ingredients refers the level of active based on the medium,

[0092] a: Significantly higher than either of single actives (p < 0.01).

[0093] It was evident from Table 1 that only when combining acetyl methionine and sodium ascorbyl 25 phosphate in certain molar ratio according to the present invention, the expression COL17A1 gene was synergistically upregulated (Sample 1). In contrast, when the molar ratio of the acetyl methionine to the sodium ascorbyl phosphate is outside the range of the present invention, a synergistical upregulation of COL17A1 gene expression was not achieved (Sample F and G).

Claims

P0001265W01 CPL12Claims1. A pharmaceutical or personal care composition comprising acetyl amino acid compound and vitamin C compound, wherein the molar ratio of the acetyl amino acid compound to the vitamin C compound is at least 7:1.

2. The composition according to claim 1 wherein the acetyl amino acid compound is selected from the group consisting of acetyl glutamic acid; acetyl glutamine; acetyl methionine; acetyl tyrosine; free acid, an amide, an ester, a lactone, an isomer thereof; salt thereof, and combination thereof.

3. The composition according to claim 1 or 2 wherein the acetyl amino acid compound is present in an amount of from 0.0001 to 10% preferably from 0.05 to 2.5% by weight of the composition.

4. The composition according to any one of the preceding claims wherein the molar ratio of the acetyl amino acid compound to the vitamin C compound is 7:1 to 300:1, preferably 7:1 to 30:1.

5. A personal care composition comprising acetyl methionine compound and vitamin C compound, wherein the molar ratio of acetyl methionine compound to the vitamin C compound is at least 7:1.

6. The composition according to claim 5 wherein the acetyl methionine compound is selected from acetyl methionine, salt of acetyl methionine, ester of acetyl methionine, salt of ester of acetyl methionine, or a mixture thereof, preferably the acetyl methionine compound is acetyl methionine.

7. The composition according to claim 5 or 6, wherein the acetyl methionine compound is present in the composition in an amount of from 0.0001 to 10%, preferably 0.05 to 2.5% by weight of the composition.

8. The composition according to any one of the preceding claims wherein the vitamin C compound comprises ascorbic acid, calcium ascorbate dihydrate, sodium ascorbate, ascorbyl glycoside, glyceryl ascorbate, 3-O-ethyl-L-ascorbic acid, methoxy peg-7 ascorbicP0001265W01 CPL13acid, ascorbyl stearate, ascorbyl tetraisopalmitate, tetrahexyldecyl ascorbate, ascorbyl phosphate, ascorbyl palmitate, or a mixture thereof, preferably the vitamin C compound is ascorbyl phosphate.

9. The composition according to any one of the preceding claims wherein the amount of the vitamin C compound of the is 0.0001 to 8% by weight of the composition, preferably 0.02 to 2% by weight of the composition.

10. The composition according to any one of the preceding claims 5 to 9 wherein the molar ratio of the acetyl methionine compound to the vitamin C compound is 7:1 to 300:1, preferably 8:1 to 15:1.

11. A method of providing the skin benefits selected from the group consisting of enhancing collagen production in the skin, improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging, would healing, and enhancing the expression of COL17A1 gene, comprising a step of topically applying to the skin the composition of the composition of the present invention.

12. Use of the composition of the present invention for providing the skin benefits selected from the group consisting of enhancing collagen production in the skin, improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging, would healing, and enhancing the expression of COL17A1 gene.

Images